The South & Central America overactive bladder treatment market is expected to grow from US$ 472.49 million in 2022 to US$ 543.53 million by 2028; it is estimated to grow at a CAGR of 2.4% from 2022 to 2028.
Increasing Number of Mergers and Acquisitions is Propelling South & Central America Overactive Bladder Treatment Market Growth
Through mergers and acquisitions (M&A), companies can gain a competitive edge by entering new markets and acquiring new technologies. The ongoing mergers and acquisitions in the overactive bladder treatment market are creating growth opportunities for various companies. In July 2021,Uro Medical strengthened its urology portfolio with the acquisition of Micron Medical, which offers wirelessly powered, injectable, microtechnology neurostimulators focused on treating overactive bladder. These neurostimulators, which can be easily incorporated into patients' daily lives, offer a convenient, safe, minimally invasive, and cost-effective urological treatment option. In February 2021, Axonics Modulation Technologies, Inc.; a medical technology company; acquired Contura Ltd. and its proprietary product, Bulkamid, which is a urethral bulking agent for women with stress urinary incontinence (SUI). Axonics produces and markets novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction. The acquisition of Contura Ltd. provides an opportunity to expand its SNM business across the world and serve the large, highly underpenetrated SUI market. The company plans to offer urogynecologists and urologists a complete suite of clinically differentiated incontinence solutions to treat their patients. Thus, increasing number of mergers and acquisitions is propelling South & Central America overactive bladder treatment market growth
South & Central America Overactive Bladder Treatment Market Overview
The South & Central America overactive bladder treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil is expected to account for the largest share of the market in the region, and it is projected to register the highest CAGR during the forecast period. The market growth is attributed to the growing geriatric population and rising prevalence of chronic disorders. The region is witnessing the high prevalence of obesity, unhealthy lifestyle patterns, and other risks, which are contributing to overactive bladder syndrome. As a result, the awareness of overactive bladder treatment has increased across the region, which is influencing the market growth in the region.
South & Central America Overactive Bladder Treatment Market Segmentation
The South & Central America overactive bladder treatment market is segmented on the basis of pharmacotherapy, disease type, and country.
- Based on pharmacotherapy, the South & Central America overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment registered the largest share of the market in 2022.
- Based on disease type, the South & Central America overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held a larger share of the market in 2022.
- Based on country, the South & Central America overactive bladder treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the market in 2022.
AbbVie Inc; Astellas Pharma Inc; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd are the leading companies operating in the South & Central America overactive bladder treatment market.
Table of Contents
1. Introduction1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 SAM Overactive Bladder Treatment Market- By Pharmacotherapy
1.3.2 SAM Overactive Bladder Treatment Market- By Disease Type
1.3.3 SAM Overactive Bladder Treatment Market - By Country
2. SAM Overactive Bladder Treatment Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SAM Overactive Bladder Treatment Market - Market Landscape
4.1 Overview
4.2 SAM PEST Analysis
4.3 Expert Opinion
5. SAM Overactive Bladder Treatment Market - Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of Urinary Incontinence
5.1.2 Growing Incidence of Urinary Tract Infections
5.2 Key Market Restraints
5.2.1 Recalls of Therapeutic Drugs
5.3 Key Market Opportunities
5.3.1 Increasing Number of Mergers and Acquisitions
5.4 Future Trends
5.4.1 Robust Pipeline of Drugs and Successive Launch of Novel Therapies
5.5 Impact analysis
6. SAM Overactive Bladder Treatment Market - SAM Analysis
6.1 SAM Overactive Bladder Treatment Market Revenue Forecast and Analysis
7. SAM Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Pharmacotherapy
7.1 Overview
7.2 SAM Overactive Bladder Treatment Market, By Pharmacotherapy 2021 & 2028 (%)
7.3 Mirabegron
7.3.1 Overview
7.3.2 Mirabegron: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.4 Botox
7.4.1 Overview
7.4.2 Botox: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.5 Neurostimulation
7.5.1 Overview
7.5.2 Neurostimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.3 Transcutaneous Sacral Nerve Stimulation
7.5.3.1 Overview
7.5.3.2 Transcutaneous Sacral Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.4 Transcutaneous Tibial Nerve Stimulation
7.5.4.1 Overview
7.5.4.2 Transcutaneous Tibial Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.5 Percutaneous Posterior Tibial Nerve Stimulation
7.5.5.1 Overview
7.5.5.2 Percutaneous Posterior Tibial Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.5.6 Others
7.5.6.1 Overview
7.5.6.2 Others: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
7.6 Anticholinergics
7.6.1 Overview
7.6.2 Anticholinergics: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.3 Solifenacin
7.6.3.1 Overview
7.6.3.2 Solifenacin: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.4 Oxybutynin
7.6.4.1 Overview
7.6.4.2 Oxybutynin: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.5 Fesoterodine
7.6.5.1 Overview
7.6.5.2 Fesoterodine: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.6 Darifenacin
7.6.6.1 Overview
7.6.6.2 Darifenacin: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.7 Tolterodine
7.6.7.1 Overview
7.6.7.2 Tolterodine: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.8 Trospium
7.6.8.1 Overview
7.6.8.2 Trospium: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.6.9 Other Anticholinergics
7.6.9.1 Overview
7.6.9.2 Other Anticholinergics: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Million)
7.7 Intravesical Instillation
7.7.1 Overview
7.7.2 Intravesical Instillation: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8. SAM Overactive Bladder Treatment Market Analysis and Forecasts To 2028 - By Disease Type
8.1 Overview
8.2 SAM Overactive Bladder Treatment Market, By Disease Type 2021 & 2028 (%)
8.3 Idiopathic Overactive Bladder
8.3.1 Overview
8.3.2 Idiopathic: Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
8.4 Neurogenic Overactive Bladder
8.4.1 Overview
8.4.2 Neurogenic: SAM Overactive Bladder Market Revenue and Forecast to 2028 (US$ Mn)
9. Overactive Bladder Treatment Market Revenue and Forecasts to 2028 - Country Analysis
Overview
9.1.2 SAM: Overactive Bladder Treatment Market, by Country, 2021 & 2028 (%)
9.1.2.1 Brazil: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
9.1.2.2 Brazil: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
9.1.2.3 Brazil: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (USD Million)
9.1.2.3.1.1 Brazil: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
9.1.2.3.1.2 Brazil Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
9.1.2.4 Brazil: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (USD Million)
9.1.3 Argentina: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
9.1.3.1 Argentina: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
9.1.3.1.1 Argentina: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (USD Million)
9.1.3.1.1.1 Argentina: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
9.1.3.1.1.2 Argentina Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
9.1.3.1.2 Argentina: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (USD Million)
9.1.3.2 Rest of SAM: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
9.1.3.2.1 Rest of SAM: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
9.1.3.2.2 Rest of SAM: Overactive Bladder Treatment Market, by Pharmacotherapy, 2019-2028 (USD Million)
9.1.3.2.2.1 Rest of SAM: Overactive Bladder Treatment Market, by Anticholinergic, 2019-2028 (US$ Million)
9.1.3.2.2.2 Rest of South & Central America Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (USD Million)
9.1.3.2.3 Rest of SAM: Overactive Bladder Treatment Market, by Disease Type, 2019-2028 (USD Million)
10. Overactive Bladder Treatment Market- Industry Landscape
10.1 Overview
10.2 Organic Developments
10.2.1 Overview
11. Company Profiles
11.1 Astellas Pharma Inc
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 AbbVie Inc
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Teva Pharmaceutical Industries Ltd
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Endo Pharmaceuticals Inc.
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Hisamitsu Pharmaceutical Co., Inc.
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Medtronic Plc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Pfizer Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
12. Appendix
12.1 About the Publisher
12.2 Glossary of Terms
List of Tables
Table 1. Brazil Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (USD Million)
Table 2. Brazil Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 3. Brazil Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 4. Brazil Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (USD Million)
Table 5. Argentina Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (USD Million)
Table 6. Argentina Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 7. Argentina Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 8. Argentina Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (USD Million)
Table 9. Rest of SAM Overactive Bladder Treatment Market, by Pharmacotherapy - Revenue and Forecast to 2028 (USD Million)
Table 10. Rest of SAM Overactive Bladder Treatment Market, by Anticholinergic - Revenue and Forecast to 2028 (US$ Million)
Table 11. Rest of SAM Overactive Bladder Treatment Market, by Neurostimulation - Revenue and Forecast to 2028 (US$ Million)
Table 12. Rest of SAM Overactive Bladder Treatment Market, by Disease Type - Revenue and Forecast to 2028 (USD Million)
Table 13. Organic Developments Done by Companies
Table 14. Glossary of Terms
List of Figures
Figure 1. SAM Overactive Bladder Treatment Market Segmentation
Figure 2. SAM Overactive Bladder Treatment Market Segmentation, By Country
Figure 3. SAM Overactive Bladder Treatment Market Overview
Figure 4. Mirabegron Segment Held Largest Share by Pharmacotherapy in SAM Overactive Bladder Treatment market
Figure 5. Argentina Is Expected to Show Remarkable Growth During the Forecast Period
Figure 7. SAM: PEST Analysis
Figure 8. SAM Overactive Bladder Treatment Market: Impact Analysis of Driver and Restraints
Figure 9. SAM Overactive Bladder Treatment Market - Revenue Forecast and Analysis - 2019- 2028
Figure 10. SAM Overactive Bladder Treatment Market, by Pharmacotherapy 2021 & 2028 (%)
Figure 11. Mirabegron: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 12. Botox: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 13. Neurostimulation: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 14. Transcutaneous Sacral Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 15. Transcutaneous Tibial Nerve Stimulation: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ MN)
Figure 16. Percutaneous Posterior Tibial Nerve: SAM Overactive Bladder Stimulation Market Revenue and Forecasts To 2028 (US$ MN)
Figure 17. Others: SAM Overactive Bladder Market Revenue and Forecasts To 2028 (US$ MN)
Figure 18. Anticholinergics: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. Solifenacin: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. Oxybutynin: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. Fesoterodine: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. Darifenacin: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. Tolterodine: SAM Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 24. Trospium: SAM Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 25. Other Anticholinergics: SAM Overactive Bladder Market Revenue and Forecasts To 2028 (US$ Million)
Figure 26. Intravesical Instillation: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 27. SAM Overactive Bladder Treatment Market, by Disease Type 2021 & 2028 (%)
Figure 28. Idiopathic: Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 29. Neurogenic: SAM Overactive Bladder Market Revenue and Forecasts to 2028 (US$ Mn)
Figure 30. SAM: Overactive Bladder Treatment Market, by Key Country - Revenue (2021) (USD Million)
Figure 31. Brazil: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
Figure 32. Argentina: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
Figure 33. Rest of SAM: Overactive Bladder Treatment Market - Revenue and Forecast to 2028 (USD Million)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AbbVie Inc
- Astellas Pharma Inc
- Endo Pharmaceuticals Inc.
- Hisamitsu Pharmaceutical Co., Inc.
- Medtronic Plc
- Pfizer Inc
- Teva Pharmaceutical Industries Ltd
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 124 |
| Published | January 2023 |
| Forecast Period | 2022 - 2028 |
| Estimated Market Value ( USD | $ 472.49 Million |
| Forecasted Market Value ( USD | $ 543.53 Million |
| Compound Annual Growth Rate | 2.4% |
